Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.

The main objective of this study is to determine the feasibility of maintaining virologic suppression on standard plasma viral load (limit of detection 37 copies / mL) of a dose reduction strategy of ATRIPLA ® once a day to three tablets per week in patients infected with HIV-1 with sustained suppression of plasma viral load standard for more than two years.

Inclusion Criteria:

• Adults (≥ 18 years)
• HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years.
• Standard plasma viral load below the limit of detection for at least 2 years.
• CD4 count above 350/mm3 at the time of the consideration for the study.
• Negative pregnancy test in women of childbearing age, and commitment acceptable contraceptive use for at least 2 weeks before day 1 and until at least 6 months after the last dose of study drug.
• Patients should be given written informed consent
• In the opinion of the investigator, be able to follow the design of the protocol visits

Exclusion Criteria:

• Patients who have experienced virologic failure prior to any antiretroviral regimen
• Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine
• Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months prior to entry of the patient in the study
• Any contraindication to study drug
• Any condition not ensure proper adherence to the study at the discretion of the attending physician of the patient
• Uncontrolled preexisting psychiatric illness
• Any current sign of alcoholism or other drug use.